FDA Grants BAVENCIO (avelumab) Approval for a Common Type of Advanced Bladder Cancer – PR Newswire (press release)
Posted: May 10, 2017 at 10:48 am
ROCKLAND, Mass. and NEW YORK, May 9, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO (avelumab) Injection for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. BAVENCIO was previously granted accelerated approval from the FDA for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). These indications are approved under accelerated approval based on tumor response and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.1
"This approval for BAVENCIO in patients with locally advanced or metastatic urothelial carcinoma exemplifies our unwavering commitment to finding new treatments for the most challenging cancers," said Luciano Rossetti, M.D., Executive Vice President, Global Head of Research & Development at the biopharma business of Merck KGaA, Darmstadt, Germany. "Coming just a few weeks after the approval for metastatic Merkel cell carcinoma, we continue to demonstrate our ability to accelerate access to innovative medicines for patients in need."
"This approval builds on the ongoing clinical development program for BAVENCIO in urothelial carcinoma and reinforces our commitment to providing new medicines to patients with difficult-to-treat cancers," said Liz Barrett, Global President, Pfizer Oncology. "By drawing on the strength of the alliance, as well as Pfizer's deep experience in genitourinary cancers, we believe BAVENCIO will be an important treatment option, and we hope it will help to improve outcomes for these patients."
Bladder cancer makes up approximately 90% of urothelial carcinomas and is the sixth most common cancer in the US.2,3 When the disease has metastasized, the five-year survival rate is approximately 5%.4 Despite advances in the treatment of locally advanced or metastatic urothelial carcinoma, the prognosis for patients remains poor and more treatment options are needed.2
"Once urothelial carcinoma progresses after treatment with chemotherapy, the five-year survival rate is alarmingly low," said Dr. Andrea Apolo, National Cancer Institute, Bethesda, MD, US. "Until recently, there had been limited innovation in urothelial carcinoma, and this approval gives us another treatment to help battle this aggressive disease."
The efficacy and safety of BAVENCIO was demonstrated in the urothelial carcinoma cohorts (N=242) of the JAVELIN Solid Tumor trial, a Phase I, open-label, single-arm, multicenter study of BAVENCIO in the treatment of various solid tumors. The urothelial carcinoma cohorts enrolled patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy or who had disease progression within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant chemotherapy regimen. These data will be presented at an upcoming medical congress.
The warnings and precautions for BAVENCIO include immune-mediated adverse reactions (such as pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and renal dysfunction and other adverse reactions), infusion-related reactions and embryo-fetal toxicity. The most common adverse reactions (reported in at least 20% of patients) in patients with locally advanced or metastatic urothelial carcinoma were fatigue (41%), infusion-related reaction (30%), musculoskeletal pain (25%), nausea (24%), decreased appetite/hypophagia (21%) and urinary tract infection (21%).1 For more information, please see Important Safety Information for BAVENCIO below.
BAVENCIO is designed to potentially engage both the adaptive and innate immune systems. By binding to PD-L1, BAVENCIO is thought to prevent tumor cells from using PD-L1 for protection against white blood cells, such as T cells, exposing them to anti-tumor responses.1 BAVENCIO has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.1
The alliance is committed to providing industry-leading patient access and reimbursement support through its CoverOne program. This program provides a spectrum of patient access and reimbursement support services intended to help patients receive appropriate access to BAVENCIO in the United States. CoverOne may be reached by phone at 844-8COVER1 (844-826-8371) or online at http://www.CoverOne.com.
About Urothelial Carcinoma Cohorts in JAVELIN Solid Tumor Trial The efficacy and safety of BAVENCIO was demonstrated in the urothelial carcinoma cohorts of the JAVELIN Solid Tumor trial, a Phase I, open-label, single-arm, multicenter study that included 242 patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum- containing chemotherapy or who had disease progression within 12 months of treatment with a platinum-containing neoadjuvant or adjuvant chemotherapy regimen who were treated with BAVENCIO.
Patients with active or a history of central nervous system metastasis; other malignancies within the last five years; an organ transplant; conditions requiring therapeutic immune suppression; or active infection with HIV, hepatitis B or C were excluded. Patients with autoimmune disease, other than type 1 diabetes, vitiligo, psoriasis, or thyroid disease that did not require immunosuppressive treatment, were excluded. Patients were included regardless of their PD-L1 status. Patients received BAVENCIO at a dose of 10 mg/kg intravenously over 60 minutes every two weeks until disease progression or unacceptable toxicity. Tumor response assessments were performed every six weeks, as assessed by an Independent Endpoint Review Committee (IERC) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Efficacy outcome measures included confirmed overall response rate, (ORR) and duration of response (DOR). Efficacy measures were evaluated in patients who were followed for a minimum of both 13 weeks and 6 months at the time of data cut-off.
Out of the total 226 patients evaluable for efficacy, 44% had non-bladder urothelial carcinoma, including 23% of patients with upper tract disease; 83% of patients had visceral metastases; 34% of patients had liver metastases. Nine patients (4%) had disease progression following prior platinum-containing neoadjuvant or adjuvant therapy only. Forty-seven percent of patients only received prior cisplatin-based regimens, 32% received only prior carboplatin-based regimens, and 20% received both cisplatin and carboplatin-based regimens.
The international clinical development program for avelumab, known as JAVELIN, involves more than 30 clinical programs, including nine Phase III trials, and more than 5,200 patients across more than 15 tumor types.
In December 2015, Merck KGaA, Darmstadt, Germany and Pfizer announced the initiation of a Phase III multicenter, multinational, randomized, open-label, parallel-arm study (JAVELIN Bladder 100) of BAVENCIO plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma whose disease did not progress after completion of first-line platinum-containing chemotherapy. This trial is currently enrolling patients.
For more information about JAVELIN trials, please visit http://www.clinicaltrials.gov.
For full prescribing information and medication guide for BAVENCIO, please see http://www.BAVENCIO.com.
IMPORTANT SAFETY INFORMATION and INDICATIONS
BAVENCIO can cause immune-mediated pneumonitis, including fatal cases. Monitor patients for signs and symptoms of pneumonitis and evaluate suspected cases with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent moderate (Grade 2) pneumonitis. Pneumonitis occurred in 1.2% (21/1738) of patients, including one (0.1%) patient with Grade 5, one (0.1%) with Grade 4, and five (0.3%) with Grade 3.
BAVENCIO can cause immune-mediated hepatitis, including fatal cases. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater hepatitis. Withhold BAVENCIO for moderate (Grade 2) immune-mediated hepatitis until resolution and permanently discontinue for severe (Grade 3) or life-threatening (Grade 4) immune-mediated hepatitis. Immune-mediated hepatitis was reported in 0.9% (16/1738) of patients, including two (0.1%) patients with Grade 5 and 11 (0.6%) with Grade 3.
BAVENCIO can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold BAVENCIO until resolution for moderate or severe (Grade 2 or 3) colitis and permanently discontinue for life-threatening (Grade 4) or recurrent (Grade 3) colitis upon re-initiation of BAVENCIO. Immune-mediated colitis occurred in 1.5% (26/1738) of patients, including seven (0.4%) with Grade 3.
BAVENCIO can cause immune-mediated endocrinopathies, including adrenal insufficiency, thyroid disorders, and type 1 diabetes mellitus.
Monitor patients for signs and symptoms of adrenal insufficiency during and after treatment, and administer corticosteroids as appropriate. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. Adrenal insufficiency was reported in 0.5% (8/1738) of patients, including one (0.1%) with Grade 3.
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation. Manage hypothyroidism with hormone replacement therapy and hyperthyroidism with medical management. Withhold BAVENCIO for severe (Grade 3) or life- threatening (Grade 4) thyroid disorders. Thyroid disorders including hypothyroidism, hyperthyroidism, and thyroiditis were reported in 6% (98/1738) of patients, including three (0.2%) with Grade 3.
Type 1 diabetes mellitus including diabetic ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Withhold BAVENCIO and administer anti-hyperglycemics or insulin in patients with severe or life-threatening (Grade 3) hyperglycemia, and resume treatment when metabolic control is achieved. Type 1 diabetes mellitus without an alternative etiology occurred in 0.1% (2/1738) of patients, including two cases of Grade 3 hyperglycemia.
BAVENCIO can cause immune-mediated nephritis and renal dysfunction. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater nephritis. Withhold BAVENCIO for moderate (Grade 2) or severe (Grade 3) nephritis until resolution to Grade 1 or lower. Permanently discontinue BAVENCIO for life-threatening (Grade 4) nephritis. Immune-mediated nephritis occurred in 0.1% (1/1738) of patients.
BAVENCIO can result in other severe and fatal immune-mediated adverse reactions involving any organ system during treatment or after treatment discontinuation. For suspected immune-mediated adverse reactions, evaluate to confirm or rule out an immune-mediated adverse reaction and to exclude other causes. Depending on the severity of the adverse reaction, withhold or permanently discontinue BAVENCIO, administer high-dose corticosteroids, and initiate hormone replacement therapy if appropriate. Resume BAVENCIO when the immune-mediated adverse reaction remains at Grade 1 or lower following a corticosteroid taper. Permanently discontinue BAVENCIO for any severe (Grade 3) immune-mediated adverse reaction that recurs and for any life-threatening (Grade 4) immune-mediated adverse reaction. The following clinically significant immune-mediated adverse reactions occurred in less than 1% of 1738 patients treated with BAVENCIO: myocarditis with fatal cases, myositis, psoriasis, arthritis, exfoliative dermatitis, erythema multiforme, pemphigoid, hypopituitarism, uveitis, Guillain-Barr syndrome, and systemic inflammatory response.
BAVENCIO can cause severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Patients should be premedicated with an antihistamine and acetaminophen prior to the first 4 infusions and for subsequent doses based upon clinical judgment and presence/severity of prior infusion reactions. Monitor patients for signs and symptoms of infusion-related reactions, including pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. Permanently discontinue BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Infusion-related reactions occurred in 25% (439/1738) of patients, including three (0.2%) patients with Grade 4 and nine (0.5%) with Grade 3.
BAVENCIO can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus including the risk of fetal death. Advise females of childbearing potential to use effective contraception during treatment with BAVENCIO and for at least 1 month after the last dose of BAVENCIO. It is not known whether BAVENCIO is excreted in human milk. Advise a lactating woman not to breastfeed during treatment and for at least 1 month after the last dose of BAVENCIO due to the potential for serious adverse reactions in breastfed infants.
The most common adverse reactions (all grades, 20%) in patients with metastatic Merkel cell carcinoma (MCC) were fatigue (50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%), infusion-related reaction (22%), rash (22%), decreased appetite (20%), and peripheral edema (20%).
Selected treatment-emergent laboratory abnormalities (all grades, 20%) in patients with metastatic MCC were lymphopenia (49%), anemia (35%), increased aspartate aminotransferase (34%), thrombocytopenia (27%), and increased alanine aminotransferase (20%).
The most common adverse reactions (all grades, 20%) in patients with locally advanced or metastatic urothelial cancer (UC) were fatigue (41%), infusion-related reaction (30%), musculoskeletal pain (25%), nausea (24%), decreased appetite/hypophagia (21%) and urinary tract infection (21%).
Selected laboratory abnormalities (grades 3-4, 3%) in patients with locally advanced or metastatic UC were hyponatremia (16%), gamma-glutamyltransferase increased (12%), lymphopenia (11%), hyperglycemia (9%), increased alkaline phosphatase (7%), anemia (6%), increased lipase (6%), hyperkalemia (3%), and increased aspartate aminotransferase (3%).
INDICATIONS
BAVENCIO is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
BAVENCIO is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
These indications are approved under accelerated approval based on tumor response and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
Please see full Prescribing Information and Medication Guide.
Avelumab has not yet been approved for any indication in any market outside of the US. As announced on October 31, 2016, the European Medicines Agency (EMA) has validated for review Merck KGaA, Darmstadt, Germany's Marketing Authorization Application for avelumab, for the proposed indication of metastatic Merkel cell carcinoma.
About BAVENCIO (avelumab) BAVENCIO is a human programmed death ligand-1 (PD-L1) blocking antibody indicated in the US for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, as well as for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.1 These indications are approved under accelerated approval based on tumor response and duration of response. Continued approval for these indications is contingent upon verification and description of clinical benefit in confirmatory trials.
BAVENCIO is not approved for any indication in any market outside the US.
Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US Immuno-oncology is a top priority for Merck KGaA, Darmstadt, Germany and Pfizer Inc. The global strategic alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Inc., New York, US, enables the companies to benefit from each other's strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck KGaA, Darmstadt, Germany. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer's PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab as a monotherapy, as well as in combination regimens, and is striving to find new ways to treat cancer.
About EMD Serono, Inc. EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany a leading science and technology company in the US and Canada focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has 1,200 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. http://www.emdserono.com
About Merck KGaA, Darmstadt, Germany All Merck KGaA, Darmstadt, Germany Press Releases are distributed by e-mail at the same time they become available on the Merck KGaA, Darmstadt, Germany Website. Please go to http://www.emdgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of 15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the "Merck" name and brand except in the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Pfizer Inc.: Working together for a healthier world At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.pfizer.com. In addition, to learn more, please visit us on http://www.pfizer.com and follow us on Twitter at @Pfizer and @PfizerNews, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice The information contained in this release is as of May 9, 2017. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about BAVENCIO (avelumab), the alliance between Merck KGaA, Darmstadt, Germany and Pfizer involving anti-PD-L1 and anti-PD-1 therapies, and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of BAVENCIO; the uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates and regulatory submission dates, as well as the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether and when drug applications may be filed in any other jurisdictions for the Indication or in any jurisdictions for any other potential indications for BAVENCIO, combination therapies or other product candidates; whether and when any such applications (including the pending application for BAVENCIO for metastatic Merkel cell carcinoma in the EU) may be approved by regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of BAVENCIO, combination therapies or other product candidates; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov and http://www.pfizer.com.
References
Your Contacts
EMD Serono Inc.
Media
Melissa Lauer
+1 781 738 5673
Investor Relations
+49 6151 72 3321
Pfizer Inc., New York, USA
Media
Sally Beatty
+1 212 733 6566
Investor Relations
Ryan Crowe
+1 212 733 8160
SOURCE EMD Serono; Pfizer
Excerpt from:
FDA Grants BAVENCIO (avelumab) Approval for a Common Type of Advanced Bladder Cancer - PR Newswire (press release)
- Correction of In-Patient Severe Hypernatremia in an 81-Year-Old Female With Hypopituitarism - Cureus - January 3rd, 2024
- Hypopituitarism: Symptoms, causes, and treatment - Medical News Today - December 25th, 2023
- Hypopituitarism - Hormonal and Metabolic Disorders - Merck Manuals ... - November 27th, 2023
- Diagnosis and Treatment of Hypopituitarism - PMC - National Center for ... - April 18th, 2023
- Hypopituitarism - StatPearls - NCBI Bookshelf - February 10th, 2023
- Panhypopituitarism: What It Is, Symptoms & Treatment - Cleveland Clinic - February 10th, 2023
- Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society ... - November 1st, 2022
- 31 days of horror movies: Orphan: First Kill is a reminder to have fun with movies - 1428 Elm - October 8th, 2022
- New to Streaming: Ken Jacobs, The Legend of Molly Johnson, Spin Me Round, The Princess & More - The Film Stage - August 20th, 2022
- Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know - Cureus - August 20th, 2022
- Global Metabolic Partnering Report 2022: Deal Trends, Players and Financials Analysis of 1100+ Deals Signed Since 2015 - ResearchAndMarkets.com -... - August 20th, 2022
- A Case of Undiagnosed Functional Gonadotroph Adenoma Leading to Ovarian Hyperstimulation Syndrome - Cureus - June 28th, 2022
- Hypopituitarism: Symptoms, Treatment & Diagnosis - May 11th, 2022
- Polyendocrine gland injury induced by an immunosuppressant | DMSO - Dove Medical Press - April 28th, 2022
- Pfizer and Biohaven's VYDURA Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of... - April 28th, 2022
- COVID-19 and hypopituitarism - DocWire News - August 16th, 2021
- Orphan: First Kill Has a Surprise Twist That Could Rival the Original's Shocking Ending - MovieWeb - May 26th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 26th, 2021
- Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival... - May 26th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 26th, 2021
- Sheehan's syndrome - Symptoms and causes - Mayo Clinic - February 19th, 2021
- atrophy | Definition, Types, & Effects | Britannica - February 19th, 2021
- Hormone Replacement in Hypopituitarism Guideline Resources ... - February 14th, 2021
- World Alopecia Market Segmentation & Impact Analysis, by Gender, Application and Region - Featuring Profiles of Key Players Cipla Inc, Johnson AG,... - December 30th, 2020
- Global Alopecia Market is Forecast to Deliver a CAGR of 5.1% Between 2019 and 2027 - GlobeNewswire - December 14th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 13th, 2020
- Alopecia Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights -... - November 10th, 2020
- Male Hypogonadism Market Projected to be Resilient During 2025 - The Market Feed - November 10th, 2020
- Alopecia Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights - KYT24 - November 8th, 2020
- U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) in... - October 23rd, 2020
- Man scared to return home after being stabbed and beaten by intruders in the middle of the night - Yorkshire Live - September 26th, 2020
- Disabled Sheffield man reveals horrific injuries after being stabbed in his own home - The Star - September 22nd, 2020
- BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine - PRNewswire - September 22nd, 2020
- Kristine Barnett: Indiana mum who abandoned 'adult' daughter who tried to kill her cleared of neglect charges - MEAWW - August 19th, 2020
- Global Alopecia Market was valued at approximately USD 2.40 billion in 2019, and is expected to generate revenue of around USD 4.45 billion by end of... - August 11th, 2020
- 20 Of The Most Shocking Plot Twists In Movies That We Never Predicted - ScoopWhoop - August 11th, 2020
- Global Alopecia Market 2020 | Analyzing The COVID-19 Impact Followed By Restraints, Opportunities And Projected Developments - Bulletin Line - August 2nd, 2020
- Diagnosis and Management of Pituitary Incidentaloma - Endocrinology Advisor - June 18th, 2020
- Male Hypogonadism Market Future Aspect Analysis and Current Trends by 2017 to 2025 - 3rd Watch News - May 21st, 2020
- Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 - PRNewswire - May 18th, 2020
- Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 - WFMZ Allentown - May 16th, 2020
- Hypopituitarism | Endocrine Society - April 13th, 2020
- Certain Types of Steroids Could Increase the Risk of Coronavirus - Myhealthyclick - April 13th, 2020
- EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO for First-Line Maintenance Treatment of... - April 10th, 2020
- Corticosteroids With COVID-19 in Asthma, Allergies, and Arthritis Patients - MedicineNet - April 9th, 2020
- How the Sunflowers Children's Action Group has brought joy to poorly youngsters in lockdown - Grimsby Live - April 9th, 2020
- Patients on Steroids With COVID-19 Might Need Rescue Steroids - Medscape - April 6th, 2020
- Patients taking steroids with COVID-19 may need rescue steroids. - NewsDio - April 6th, 2020
- EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study - P&T Community - March 18th, 2020
- Is dwarf boy Quaden Bayles 18-year-old or just 9? Internet is divided and debate continues - International Business Times, Singapore Edition - February 28th, 2020
- 'Orphan' Prequel to Tell the Origins of 'Esther' - Bloody Disgusting - February 20th, 2020
- Acromegaly Treatment Industry 2020 Global Market Size, Demand, Growth Prospects, Key Insights, Top Companies and Forecast till 2025 - Instant Tech... - February 18th, 2020
- The motive within the serve of this man's suffering became once hiding in undeniable look - Invest Records - January 28th, 2020
- Male Hypogonadism Market Analytical Overview and Growth Opportunities by 2025 - Fusion Science Academy - January 17th, 2020
- Rare Skeleton Points to Compassion, Care, and Tragedy in Prehistoric China - Gizmodo - December 21st, 2019
- Acromegaly Treatment Industry 2019 Global Market Size, Demand, Growth Prospects, Key Insights, Top Companies and Forecast till 2025 - Market Research... - December 20th, 2019
- 5,000-Year-Old Human Found with 'Extremely Rare' Form of Dwarfism - Livescience.com - December 17th, 2019
- How Hypopituitarism is Treated | Learn More About ... - December 11th, 2019
- Acromegaly Treatment Industry 2019 Global Market Size, Demand, Growth Prospects, Key Insights, Top Companies and Forecast till 2025 - VaporBlash - December 5th, 2019
- Alopecia Market Outlook and Opportunities in Grooming Regions with Forecast to 2027 | CAPILLUS, Sun Pharmaceutical Industries, Cipla, Merck and Co,... - November 24th, 2019
- Look inside the old Natwest in Prescot after its total transformation - Liverpool Echo - November 2nd, 2019
- PRACTICALLY ACTIVE: Love your liver and it will love you back - Arkansas Democrat-Gazette - October 9th, 2019
- Male Hypogonadism Market Growth Opportunities and Dynamic Business by 2025 - NewsStoner - September 27th, 2019
- What causes prolonged menstrual bleeding? - The New Times - September 24th, 2019
- CHMP Adopts Positive Opinion for BAVENCIO (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma -... - September 24th, 2019
- Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio - Yahoo Finance - September 24th, 2019
- Acute Hypopituitarism: Overview, Diagnostic Considerations ... - May 29th, 2019
- Hypopituitarism | Endocrinology | Dartmouth-Hitchcock - May 2nd, 2019
- Hypopituitarism | Johns Hopkins Medicine - April 11th, 2019
- Hypopituitarism Symptoms & Causes | Boston Children's Hospital - March 6th, 2019
- Endocrine Diseases in Pregnancy | GLOWM - February 18th, 2019
- Non-Functioning Tumors (Endocrine-Inactive Tumors ... - January 29th, 2019
- Steroid Replacement Doses for Hypopituitary Patients ... - January 24th, 2019
- Hypopituitarism | UCLA Health - October 7th, 2018
- Hypopituitarism Disease Reference Guide - Drugs.com - October 3rd, 2018
- Hypopituitarism Treatment & Causes | Lurie Children's - October 3rd, 2018
- Hypopituitarism | You and Your Hormones from the Society for ... - August 23rd, 2018
- Panhypopituitarism: Practice Essentials, Pathophysiology ... - August 23rd, 2018
- Hypopituitarism | Lifespan - August 23rd, 2018
- OMIM Entry - # 146510 - PALLISTER-HALL SYNDROME; PHS - July 26th, 2018